EUVIMEDEUVIMED entdecken
Netzwerk-MetaanalyseSystematische Übersicht

Efficacy and Safety of GLP ‐1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA

Binayak Sinha, Samit Ghosal iD

Obesity · 2025-11 · 33 (11) · 2046-2054

DOI: 10.1002/oby.24360 ↗

Kurz gefasst

Netzwerk-Metaanalyse in der Zeitschrift Obesity, online erschienen am 20.07.2025. Verfasst von Binayak Sinha und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Manipal Hospital, Kolkata, India. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Obesity, Overweight, Weight Loss. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To compare the efficacy and safety of GLP‐1 receptor agonists (GLP‐1RAs), dual agonists (GLP‐1RAs/GIP or GCGR), and retatrutide (GLP‐1/GIP/glucagon) for weight loss in adults with overweight or obesity.

Methods

We conducted a systematic review and Bayesian network meta‐analysis (NMA) of 19 randomized controlled trials (RCTs) including 29,506 adults (BMI ≥ 25 kg/m 2 ), assessing liraglutide, semaglutide, survodutide, tirzepatide, retatrutide, and placebo. Outcomes included mean weight loss, achievement of ≥ 5%, ≥ 10%, and ≥ 15% weight loss, waist circumference (WC), BMI, and adverse events (AEs) at ≥ 36 weeks. Subgroup and meta‐regression analyses evaluated the impact of diabetes status, sex, age, and BMI.

Results

Retatrutide and dual agonists achieved equivalent mean weight loss (−11.0 kg), surpassing GLP‐1RAs (−9.0 kg), with retatrutide excelling at achieving ≥ 15% weight loss (OR 54.6). Dual agonists and GLP‐1RAs followed (OR 16.4 and 9.0, respectively). Retatrutide had the highest AE risk. Meta‐regression showed type 2 diabetes mellitus (T2DM) reduced weight loss by 4.338 kg for GLP‐1RAs and 5.016 kg for dual agonists, with enhanced outcomes in female‐dominant or high‐BMI cohorts.

Conclusions

Retatrutide offers superior weight loss efficacy but with a higher AE risk. Dual agonists provide a favorable efficacy–safety balance. Personalized treatment selection based on patient characteristics is recommended. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsObesityOverweightWeight LossAdultFemaleHumansMaleBayes TheoremBody Mass IndexDiabetes Mellitus, Type 2Glucagon-Like PeptidesHypoglycemic AgentsLiraglutideRandomized Controlled Trials as TopicTirzepatideTreatment OutcomeFatty AcidsPeptidesGlucagon-Like Peptide 1Semaglutide

Stichwörter der Autor:innen

GLP‐1 receptor agonistsadverse eventsdual agonistsnetwork meta‐analysisobesityretatrutideweight loss

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like PeptidesHypoglycemic AgentsLiraglutideTirzepatideFatty AcidsPeptidesGlucagon-Like Peptide 1Semaglutideretatrutide

Autor:innen und Institutionen

  • Department of Endocrinology, Manipal Hospital, Kolkata, India.
  • Department of Internal Medicine, Nightingale Hospital, Kolkata, India.

ORCID-Profile: Samit Ghosal

Zitieren

APA

Sinha, B., & Ghosal, S. (2025). Efficacy and Safety of GLP ‐1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA. Obesity, 33(11), 2046-2054. https://doi.org/10.1002/oby.24360

Vancouver

Sinha B, Ghosal S. Efficacy and Safety of GLP ‐1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA. Obesity. 2025;33(11):2046-2054. doi:10.1002/oby.24360

BibTeX
@article{Sinha2025,
  author = {Sinha, Binayak and Ghosal, Samit},
  title = {Efficacy and Safety of GLP ‐1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA},
  journal = {Obesity},
  year = {2025},
  volume = {33},
  number = {11},
  pages = {2046--2054},
  doi = {10.1002/oby.24360}
}
Kostenlos starten →